Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

By D. Hanahan, G. Bergers, E. Bergsland. Journal of Clinical Investigation, 2000

872 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. (2004, background): “Notably, in another mouse model, that of pancreatic islet carcinoma, several classical MMP inhibitors have been found to be efficacious against early-stage but not late-stage tumors when used as monotherapy (perhaps because of the “tumstatin effect”); by contrast, a combinatorial regimen involving a”
Combination therapy in combating cancer (2017, background): “However, combination therapy can produce a more effective treatment response in fewer cycles, and therefore this treatment modality reduces the incidence of resistance [19, 20].”
Mechanisms of Drug Resistance in Cancer Chemotherapy (2005, background): “which support tumour cell growth. This involves combining anti-angiogenic drugs with a more frequent regimen of cytotoxic agents; endothelial cells are more susceptible to CTX and a lower dose of CTX agents can be used, resulting in reduced side-effects [”
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems (2013, background): “This combinational design of nanoparticles is synthesised via an imine reaction between oxidised dextran and PEI of a low molecular weight.([90]) Low molecular weight PEI is vital as cytotoxicity increases relative to the molecular weight.”